8-K: Cibus Reports Fourth Quarter Financial Results and Provides Business Update, Highlighting Progress in Gene Editing Technologies

Cibus, Inc. announced its Q4 2024 financial results and provided a business update, emphasizing advancements in its gene editing technologies and commercialization efforts.

Summary

• Cibus, Inc., a biotechnology company specializing in gene editing for agricultural traits, announced its Q4 2024 financial results and provided a business update.
• Key achievements include advancing EU Trilogue discussions on New Genomic Techniques (NGTs) and receiving approval for field research of gene-edited rice in California.
• The company is progressing with its herbicide tolerance trait commercialization efforts through collaborations with Albaugh LLC and RTDC Corporation Limited.
• Cibus is also developing Sclerotinia (White Mold) resistance traits, with successful edits in Canola for a fourth mode of action.
• An AI-powered gene discovery partnership with Biographica aims to enhance disease resistance in Canola and Oilseed Rape.
• Progress is being made on an operational Soybean platform, with breakthrough initial HT2 trait edits targeting a 75 million acre market.
• The company's Rapid Trait Development System (RTDS) enables editing of customer's elite germplasm in under 12 months.
• Cibus has agreements with four customers, including major Rice seed companies in North and Latin America, to place its HT traits in their elite germplasm.
• Successful initial PSR field trials for WOSR were completed in the UK for multiple customers.
• In January 2025, the Company successfully edited a Soybean cell for its HT2 trait, achieving sufficiently high editing rates that enabled expanded development of its Soybean platform.
• Cibus expects existing cash and cash equivalents, along with proceeds from a registered direct offering, to fund operations into late in the third quarter of 2025.
• The company is evaluating strategic alternatives to maximize shareholder value.
• The net loss for Q4 2024 was $25.8 million, compared to $277.2 million in the year-ago period, primarily due to a non-cash goodwill impairment in 2023.
• Cibus expects to report development progress in its quarterly reports and has set milestone targets for its priority programs in 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to advancements in gene editing technologies, regulatory progress, and strategic collaborations. However, concerns about near-term funding needs and ongoing financial losses temper the overall outlook.

Positives

• Advancements in regulatory approvals for gene-edited crops, particularly in the EU and California, are a positive sign for future commercialization.
• Collaborations with Albaugh LLC, RTDC Corporation Limited, and Biographica strengthen Cibus' development and commercialization efforts.
• Successful edits in Canola for multiple modes of action in Sclerotinia resistance demonstrate progress towards a durable trait.
• The AI-powered gene discovery partnership with Biographica could accelerate the identification of novel genetic targets.
• The successful editing of Soybean cells for the HT2 trait opens up a significant market opportunity.
• The Rapid Trait Development System (RTDS) offers a competitive advantage by enabling rapid trait development and commercialization.
• The registered direct offering for gross proceeds of $22.6 million in January 2025 strengthens the company's financial position.
• Cost-saving initiatives are expected to reduce monthly cash use by approximately 20%.

Negatives

• The company's cash and cash equivalents are expected to fund operations only into late in the third quarter of 2025, raising concerns about near-term funding needs.
• The net loss for Q4 2024 was $25.8 million, indicating ongoing financial challenges.
• The company is evaluating strategic alternatives to maximize shareholder value, suggesting potential strategic changes or challenges.
• Year-over-year comparisons are not comparable as 2024 includes the combined company whereas 2023 only includes Legacy Calyxt for the first five months.

Risks

• Cibus' need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all.
• Challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights.
• Increased or unanticipated time and resources required for Cibus' platform or trait product development efforts.
• Cibus' reliance on third parties in connection with its development activities.
• Challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products.
• The risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits.
• Delays or disruptions in the Company's platform or trait product development efforts, particularly with respect to its non-Rice and non-disease projects in light of the Company's realigned strategic priorities.
• Challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale.
• Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses.
• Regulatory developments that disfavor or impose significant burdens on gene-editing processes or products.
• Delays and uncertainties regarding regulatory developments in the European Union.
• Commodity prices and other market risks facing the agricultural sector.
• Technological developments that could render Cibus' technologies obsolete.
• Changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates.
• Dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan.

Future Outlook

Cibus intends to report ordinary course development progress and achievements in connection with its quarterly reporting process and has outlined key milestones for its Rice, Soybean, Sclerotinia, HT2 in Canola, and Sustainable Ingredient Development programs for 2025.

Management Comments

• 'I am energized by the momentum we're building across our key markets,' stated Peter Beetham, Co-Founder, Interim CEO, President and COO.
• Peter Beetham believes the opportunities for Cibus' gene-edited traits are materializing now.
• Peter Beetham believes Cibus is positioned to capture significant value for its shareholders due to progress in traits, field trials, and the regulatory environment.
• Peter Beetham states that Cibus' Rapid Trait Development System (RTDS) enables them to edit a customer's elite germplasm and return it with a specific trait in under 12 months.
• Peter Beetham states that Cibus' standardized platform rapidly delivers traits to seed companies that help farmers address their most pressing productivity challenges.

Industry Context

The announcement highlights the increasing importance of gene editing technologies in agriculture, particularly in addressing challenges related to weed management, disease resistance, and sustainable ingredient development. The progress in regulatory approvals, especially in the EU, signals a growing acceptance of these technologies, which could facilitate international trade and benefit growers.

Comparison to Industry Standards

• Cibus' RTDS system, which aims to deliver edited germplasm within 12 months, positions it competitively against traditional breeding methods that often take several years.
• Companies like Bayer, Corteva, and Syngenta also invest heavily in trait development, but Cibus' focus on gene editing and its RTDS system could offer a faster and more precise approach.
• The collaboration with Biographica to leverage AI for gene discovery aligns with the industry trend of using advanced technologies to accelerate innovation.
• The development of sustainable ingredients for CPG companies reflects a broader industry focus on mitigating environmental impacts and meeting consumer demand for sustainable products.

Related Party Transactions

• Royalty liability interest expense related parties was $8.2 million for the quarter ended December 31, 2024, compared to $8.1 million in the year-ago period.

Stakeholder Impact

• Shareholders: The company is evaluating strategic alternatives to maximize shareholder value, which could lead to significant changes.
• Employees: Cost-saving initiatives, including facility consolidation, may impact employees.
• Customers: Progress in trait development and commercialization could provide farmers with improved crop varieties.
• Suppliers: Collaborations with Albaugh LLC and RTDC Corporation Limited could impact suppliers of herbicides and other agricultural inputs.
• Creditors: The company's financial position and need for additional funding may affect creditors.

Next Steps

• Expand commercial relationships with Rice seed companies across North and South America.
• Expect first trait validation trials in Latin America.
• Expect to prepare delivery of initial traits to a Latin American customer by end of 2025.
• Expect HT2 edits in Soybean plants in 2025, building upon successful edits in Soybean cells earlier in 2025.
• Field trials for third and fourth modes of action in Canola planned for 2025.
• Expect early results from controlled environment testing for fourth mode of action in Canola in first quarter 2025.
• Expect initial field trial data for HT2 in Canola in 2025.
• Continue progress on our partner-funded project to develop sustainable low carbon ingredients or materials for the CPG industry that do not negatively impact the environment during production, use, or disposal.
• Expect to receive nominal revenues associated with the ongoing commercialization efforts for the Company's sustainable ingredient biofragrance products.

Key Dates

Keywords

gene editing, agricultural biotechnology, plant traits, herbicide tolerance, Sclerotinia resistance, soybean platform, RTDS, rice, canola, financial results